The AQUA-FONTIS study: protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome

Johannes W Dietrich, Axel Stachon, Biljana Antic, Harald H Klein, Steffen Hering, Johannes W Dietrich, Axel Stachon, Biljana Antic, Harald H Klein, Steffen Hering

Abstract

Background: Non-thyroidal illness syndrome (NTIS) is a characteristic functional constellation of thyrotropic feedback control that frequently occurs in critically ill patients. Although this condition is associated with significantly increased morbidity and mortality, there is still controversy on whether NTIS is caused by artefacts, is a form of beneficial adaptation, or is a disorder requiring treatment. Trials investigating substitution therapy of NTIS revealed contradictory results. The comparison of heterogeneous patient cohorts may be the cause for those inconsistencies.

Objectives: Primary objective of this study is the identification and differentiation of different functional states of thyrotropic feedback control in order to define relevant evaluation criteria for the prognosis of affected patients. Furthermore, we intend to assess the significance of an innovative physiological index approach (SPINA) in differential diagnosis between NTIS and latent (so-called "sub-clinical") thyrotoxicosis.Secondary objective is observation of variables that quantify distinct components of NTIS in the context of independent predictors of evolution, survival or pathophysiological condition and influencing or disturbing factors like medication.

Design: The approach to a quantitative follow-up of non-thyroidal illness syndrome (AQUA FONTIS study) is designed as both a cross-sectional and prospective longitudinal observation trial in critically ill patients. Patients are observed in at least two evaluation points with consecutive assessments of thyroid status, physiological and clinical data in additional weekly observations up to discharge. A second part of the study investigates the neuropsychological impact of NTIS and medium-term outcomes.The study design incorporates a two-module structure that covers a reduced protocol in form of an observation trial before patients give informed consent. Additional investigations are performed if and after patients agree in participation.

Trial registration: ClinicalTrials.gov NCT00591032.

Figures

Figure 1
Figure 1
Flowchart of the AQUA-FONTIS study with its two intertwined modules. See text and table 5 for detailed information.

References

    1. Berghe G Van den. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol. 2002;23:370–391. doi: 10.1016/S0091-3022(02)00006-7.
    1. De Groot LJ. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Crit Care Clin. 2006;22:57–86. doi: 10.1016/j.ccc.2005.10.001.
    1. Rothenbuchner G, Loos U, Kiessling WR, Birk J, Pfeiffer EF. The influence of total starvation on the pituitary-thyroid-axis in obese individuals. Acta Endocrinol Suppl (Copenh) 1973;173:144.
    1. Portnay GI, O'Brian JT, Bush J, Vagenakis AG, Azizi F, Arky RA, Ingbar SH, Braverman LE. The effect of starvation on the concentration and binding of thyroxine and triiodothyronine in serum and on the response to TRH. J Clin Endocrinol Metab. 1974;39:191–194.
    1. Chopra IJ. Nonthyroidal illness syndrome or euthyroid sick syndrome? Endocr Pract. 1996;2:45–52.
    1. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107:708–713. doi: 10.1161/01.CIR.0000048124.64204.3F.
    1. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999;84:151–164. doi: 10.1210/jc.84.1.151.
    1. Scoscia E, Baglioni S, Eslami A, Iervasi G, Monti S, Todisco T. Low triiodothyronine (T3) state: a predictor of outcome in respiratory failure? Results of a clinical pilot study. Eur J Endocrinol. 2004;151:557–560. doi: 10.1530/eje.0.1510557.
    1. Klemperer JD, Klein IL, Ojamaa K, Helm RE, Gomez M, Isom OW, Krieger KH. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg. 1996;61:1323–1327. doi: 10.1016/0003-4975(96)00102-6.
    1. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333:1522–1527. doi: 10.1056/NEJM199512073332302.
    1. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, Keogh BE, Mascaro J, Riddington DW, Rooney SJ, Townend JN, Wilson IC, Bonser RS. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation. 2006;114:I245–250.
    1. Wyne KL. The role of thyroid hormone therapy in acutely ill cardiac patients. Crit Care. 2005;9:333–334. doi: 10.1186/cc3738.
    1. Magalhaes AP, Gus M, Silva LB, Schaan BD. Oral triiodothyronine for the prevention of thyroid hormone reduction in adult valvular cardiac surgery. Braz J Med Biol Res. 2006;39:969–978. doi: 10.1590/S0100-879X2006000700015.
    1. Guden M, Akpinar B, Saggbas E, Sanisoglu I, Cakali E, Bayindir O. Effects of intravenous triiodothyronine during coronary artery bypass surgery. Asian Cardiovasc Thorac Ann. 2002;10:219–222.
    1. Ronald A, Dunning J. Does perioperative thyroxine have a role during adult cardiac surgery? Interact Cardiovasc Thorac Surg. 2006;5:166–178. doi: 10.1510/icvts.2006.128363.
    1. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000;57:293–298. doi: 10.1046/j.1523-1755.2000.00827.x.
    1. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63:1–8.
    1. Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med. 1995;333:1562–1563. doi: 10.1056/NEJM199512073332310.
    1. Caplan RH. Comment on dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999;84:2261–2262. doi: 10.1210/jc.84.6.2261-a.
    1. Angstwurm MW, Schopohl J, Gaertner R. Selenium substitution has no direct effect on thyroid hormone metabolism in critically ill patients. Eur J Endocrinol. 2004;151:47–54. doi: 10.1530/eje.0.1510047.
    1. Dietrich JW, Fischer MR, Jauch J, Pantke E, Gärtner R, Pickardt CR. SPINA-THYR: A novel systems theoretic approach to determine the secretion capacity of the thyroid gland. European Journal of Internal Medicine. 1999;10:S34.
    1. Anonymous . International Classification of Diseases (ICD) World Health Organization (WHO);
    1. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–277.
    1. Pohlenz J, Weiss RE, Macchia PE, Pannain S, Lau IT, Ho H, Refetoff S. Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor beta gene. J Clin Endocrinol Metab. 1999;84:3919–3928. doi: 10.1210/jc.84.11.3919.
    1. Graham JW. Missing Data Analysis: Making It Work in the Real World. Annu Rev Psychol. 2008
    1. Druml C. Informed consent of incapable (ICU) patients in Europe: existing laws and the EU Directive. Curr Opin Crit Care. 2004;10:570–573. doi: 10.1097/01.ccx.0000144765.73540.89.
    1. Jansen TC, Kompanje EJ, Druml C, Menon DK, Wiedermann CJ, Bakker J. Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not? Intensive Care Med. 2007;33:894–900. doi: 10.1007/s00134-007-0580-8.
    1. Anonymous Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) BGBl. 2007;I:1066.
    1. Anonymous Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001;L 121:33–44.
    1. Anonymous Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. Off J Eur Union. 2005;L 91:13–19.
    1. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. doi: 10.1371/journal.pmed.0040297.
    1. Iwanowski P, Budaj A, Czlonkowska A, Wasek W, Kozlowska-Boszko B, Oledzka U, Maselbas W. Informed consent for clinical trials in acute coronary syndromes and stroke following the European Clinical Trials Directive: investigators' experiences and attitudes. Trials. 2008;9:45. doi: 10.1186/1745-6215-9-45.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する